Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Cabozantinib Real-World Effectiveness in the First-Through Fourth-Line Settings for the Treatment of Metastatic Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database ConsortiumCancer Med 2021 Jan 18;[EPub Ahead of Print], CL Gan, S Dudani, JC Wells, F Donskov, SK Pal, N Dizman, N Rathi, B Beuselinck, F Yan, AA Lalani, A Hansen, B Szabados, G de Velasco, B Tran, JL Lee, UN Vaishampayan, GA Bjarnason, M Subasri, TK Choueiri, DYC Heng
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.